Our comprehensive and expanding portfolio of ADHD medicines are designed to provide more favorable results in a range of formulations that are easily administered to both children and adults.
We anticipate that we will continue expanding our innovative ADHD portfolio in the near term with a therapy expected to provide favorable effects in patients with autism spectrum disorders. We aim to develop new medications that could have a substantial impact on the lives of patients with ADHD.
PHASE 2
TRN-218
A once daily, oral suspension, extended-release treatment under investigation in pediatric patients with ADHD, TRN-218 is designed with a profile expected to be favorable for autism spectrum disorder (ASD) patients.
ADHD is a very common comorbidity of ASD,
affecting 50-70% of those with the disorder.10
10 Hours, C, et al. “ASD and ADHD Comorbidity: What Are We Talking About?.” Frontiers in Psychiatry. Feb 2022: (13); 837424.